Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

It is estimated that over 50% of HCC cases worldwide are related to chronic HBV. There are approximately 350-400 million people across the world infected with HBV, the majority reside in or originate from Asia. Each year HBV accounts for 749,000 new cases of HCC and 692,000 HCC-related deaths. The annual incidence of HCC is estimated to be \<1% for non-cirrhotic HBV infected patients and 2-3% for those with cirrhosis. While the most approved nucleos(t)ide analogues (NA) suppress HBV replication through inhibition of HBV-DNA polymerase and are reported to reduce the risk of HCC incidence, howe

Trial Details

NCT ID

NCT03899428

Phase

PHASE2

Sponsor

Humanity & Health Medical Group Limited

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

Durvalumab
Sorafenib
Lenvatinib
Regorafenib
Cabozantinib

Locations (sample)

Hong Kong, Hong Kong SAR, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

HBsAg positive with serum HBsAg levels ≥ 2 log IU/ml
Age ≥ 18 years old on the day of consent
Capable of understanding and complying with the protocol requirements and signed informed consent
Documented histological or cytological diagnosis of HCC within 1 year

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →